Toxicity Assessment
Objective: Evaluation of FPS-ZM1 toxicity in mice to assess safety profile of the RAGE-specific inhibitor
This is a Toxicity Assessment protocol using mouse as the model organism. The procedure involves 1 procedural steps, 1 materials. Extracted from a 2012 paper published in Journal of Clinical Investigation.
Model and subjects
mouse • APP sw/0 transgenic mice (aged) • unknown • aged • not specified
Study window
Estimated timing pending
Core workflow
FPS-ZM1 Administration and Toxicity Assessment
Primary readouts
- Toxicity assessment of FPS-ZM1 in mice
- Blood-brain barrier penetration capability
- Safety profile of the compound
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
FPS-ZM1 Administration and Toxicity Assessment
FPS-ZM1 was administered to mice and evaluated for toxicity. The compound was assessed for its ability to cross the blood-brain barrier and its safety profile in vivo.
Note: FPS-ZM1 demonstrated nontoxic properties in mice during the study period
View evidence from paper
“FPS-ZM1 was nontoxic to mice and readily crossed the blood-brain barrier (BBB)”